RxDoctor Payments Data

Deeann Sutter

Psychiatric/Mental Health · Harrison, ARNPI 1841911831

Payments from drug & device makers

$841in general payments, 2019–2025

Across 47 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$184
  • Alkermes, Inc.$99
  • Neurocrine Biosciences, Inc.$80
  • Otsuka America Pharmaceutical, Inc.$77
  • Supernus Pharmaceuticals, Inc.$74
  • Takeda Pharmaceuticals U.S.A., Inc.$73
  • plus $253 from 7 others

What the payments were for

  • Food & beverage$841100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$841 in reported general payments places this provider in the 50th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$23,092
Medicare patients
29
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$186,027
Invega SustennaPaliperidone Palmitate13$50,037
VraylarCariprazine Hcl32$45,226
CaplytaLumateperone Tosylate18$27,334
Paliperidone ErPaliperidone42$7,736
Atomoxetine Hcl43$3,136
Desvenlafaxine Succinate ErDesvenlafaxine Succinate70$2,718
Buspirone Hcl142$2,106
Duloxetine Hcl42$1,758
Clomipramine Hcl12$1,369
Oxcarbazepine48$1,323
Lamotrigine88$1,264
Quetiapine Fumarate44$1,232
Aripiprazole59$890
Gabapentin54$761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$80$186,02721 claims
Johnson & JohnsonInvega Sustenna$37$50,03713 claims
AbbVieVraylar$184$45,22632 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$31$27,33418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Harrison

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →